



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Apoptotic Tumor Cell-Derived Extracellular Vesicles as Important Regulators of the Onco-Regenerative Niche

Citation for published version:

Gregory, CD & Dransfield, I 2018, 'Apoptotic Tumor Cell-Derived Extracellular Vesicles as Important Regulators of the Onco-Regenerative Niche' *Frontiers in Immunology*, vol 9, pp. 1111. DOI: 10.3389/fimmu.2018.01111

Digital Object Identifier (DOI):

[10.3389/fimmu.2018.01111](https://doi.org/10.3389/fimmu.2018.01111)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Frontiers in Immunology

Publisher Rights Statement:

Copyright © 2018 Gregory and Dransfield. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Apoptotic Tumor Cell-Derived Extracellular Vesicles as Important Regulators of the Onco-Regenerative Niche

Christopher D. Gregory* and Ian Dransfield

Medical Research Council Centre for Inflammation Research at the University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, United Kingdom

OPEN ACCESS

Edited by:

Shohei Hori,
The University of Tokyo, Japan

Reviewed by:

Ai Kotani,
Tokai University Isehara
Hospital, Japan
Naohiro Seo,
Mie University, Japan

*Correspondence:

Christopher D. Gregory
chris.gregory@ed.ac.uk

Specialty section:

This article was submitted
to Immunological Tolerance
and Regulation,
a section of the journal
Frontiers in Immunology

Received: 07 March 2018

Accepted: 03 May 2018

Published: 23 May 2018

Citation:

Gregory CD and Dransfield I (2018)
Apoptotic Tumor Cell-Derived
Extracellular Vesicles as
Important Regulators of the
Onco-Regenerative Niche.
Front. Immunol. 9:1111.
doi: 10.3389/fimmu.2018.01111

Cells undergoing apoptosis produce heterogeneous populations of membrane delimited extracellular vesicles (Apo-EVs) which vary not only in size—from tens of nanometers to several microns—but also in molecular composition and cargo. Apo-EVs carry a variety of potentially biologically active components, including small molecules, proteins, and nucleic acids. Larger forms of Apo-EVs, commonly termed “apoptotic bodies,” can carry organelles, such as mitochondria and nuclear fragments. Molecules displayed on the surface of extracellular vesicles (EVs) can contribute substantially to their size, as well as their functions. Thus far, relatively little is known of the functional significance of Apo-EVs apart from their roles in fragmentation of dying cells and indicated immunomodulatory activities. Here, we discuss EV production by dying tumor cells and consider the possible roles of Apo-EVs in a cell death-driven sector of the tumor microenvironment known as the onco-regenerative niche (ORN). We propose that tumor-derived Apo-EVs are significant vehicles of the ORN, functioning as critical intercellular communicators that activate oncogenic tissue repair and regeneration pathways. We highlight important outstanding questions and suggest that Apo-EVs may harbor novel therapeutic targets.

Keywords: extracellular vesicles, apoptosis, inflammation and cancer, tumor microenvironment, angiogenesis, tissue repair and regeneration, macrophage activation, tumor biology

INTRODUCTION: APOPTOSIS, AND THE ONCO-REGENERATIVE NICHE (ORN)

In addition to its activities in developmental sculpting and adult tissue involution, apoptosis is renowned for its capacity to regulate tissue turnover and homeostasis in which, simplistically, the expansion of cell populations is balanced by regulated cell death (and *vice versa*). In cancer, this balance between cell gain and cell loss becomes dysregulated, resulting in accumulation of tumor cells and net growth of neoplastic tissues (**Figure 1**). By effecting controlled cell deletion, apoptosis imposes a brake on oncogenesis, a logical concept that has long been proven and is widely accepted. Indeed, inhibition of the tumor suppressor function of apoptosis led to the categorization of a new class of oncogenes—*BCL2* being the prototypic member—that could promote cell survival through suppression of apoptosis and thereby impose an oncogenic imbalance on the cell birth/cell death equation (1). Furthermore, the apoptosis effector protease, caspase-8, is mutated in multiple cancer types and the survival pathway PI3K/Akt/mTOR is dysregulated frequently in tumors (2). By contrast,




FIGURE 1 | Left: oncogenic extracellular vesicle (EV) networks in the onco-regenerative niche (ORN). Schematic representation of the ORN illustrating the potential roles of Apo-EVs from dying tumor cells (Apo) in providing oncogenic signals to neighboring cells in the niche, exemplified by macrophages (M), viable tumor cells (Tu), and endothelial cells (E). We propose that Apo-EVs target such cells and modulate cellular functions, including macrophage polarization toward a reparative phenotype (M2-like activation state), promotion of tumor cell survival and proliferation, and angiogenesis. EVs from viable cells (Via-EVs) of tumor and stromal cell origin also seem likely to participate in these processes. Right: mechanisms of cell targeting and modulation by (Apo)-EVs. Examples of possible modes of interaction of Apo-EVs with target cells that may lead to modulation of cellular functions with or without transfer of intact EV cargoes (biologically active cargoes represented by small red circles). 1. Membrane fusion (receptor-dependent or -independent) permits transfer of EV cargoes to cytosolic locations. 2. Docking of EVs through receptor–ligand interaction may activate intracellular signaling pathways in the absence of cargo transfer. Ligands such as phosphatidylserine (PtdSer) (green) exposed at EV surfaces may interact directly or indirectly with target cell receptors (examples in the case of PtdSer including BAI1, TIM-4, Stab1/2, Axl, Mer, as well as integrins $\alpha v\beta 3$ and $\alpha v\beta 5$). 3. Endocytic pathways (including phagocytosis) resulting in lysosomal degradation of cargoes are also likely to modulate cellular functions such as through metabolite supply and *via* receptor ligation. 4. Putative endocytic uptake of EVs without lysosomal degradation. We propose that Apo-EV cargoes are transferred intact to multiple intracellular compartments *via* this type of pathway.

pro-apoptotic regulators such as p53 and BIM (3) among others have firmly established tumor-suppressive roles for apoptosis. For these and other reasons, the capacity to evade apoptosis has become a well-accepted hallmark of cancer (4).

However, set opposite its tumor suppressor functions, the apoptosis machinery can endow dying cells with the ability to stimulate proliferation of neighboring cells, either as part of developmental programmes or in tissue repair and regeneration in adult tissues (5–9). High levels of apoptosis are commonly associated with poor prognosis in multiple cancer types (10–17) and expression of pro-apoptotic effector molecules such as active Caspase-3 and Bax can correlate with aggressive disease (18, 19). Furthermore, low-level activation of the apoptosis programme can promote genomic instability and oncogenic transformation (20).

Emerging evidence suggests strongly that both constitutive and therapy-induced apoptosis can engender pro-oncogenic responses that enhance tumor growth and cause post-therapeutic relapse (21–24). In this scenario, tumor-cell apoptosis itself promotes imbalance in the cell birth/cell death equation that ultimately favors net tumor growth. Such regenerative effects of apoptosis in the context of the tumor microenvironment led one of us to propose recently the concept of the ORN: a tumor-promoting network of tumor cells, stromal cells, and immune cells which, together with associated extracellular components, including EVs, soluble factors and matrix molecules,

is orchestrated by tumor-cell apoptosis (Figure 1) (25, 26). We speculate that pervasive apoptotic tumor cell-derived signals in the ORN provide important pathways for tumor growth, metastasis and to post-therapeutic relapse. Here, we consider the potential roles of apoptotic tumor cell-derived EVs in providing such signals.

APO-EVs AND APOPTOTIC BODIES

It is becoming increasingly clear that EVs are important intercellular communication vehicles in the tumor microenvironment, shuttling an array of biologically active molecules reciprocally between tumor and non-tumor cells, modulating the development of primary tumors and metastases. We propose that Apo-EVs—as well as EVs generated in viable cells responding to their apoptotic neighbors—are important elements of the ORN (Figure 1). EV production is a well-established hallmark of apoptosis, as is surface blebbing (zeiosis) of the plasma membrane in cells responding to apoptosis stimuli. Blebs may be important precursors to Apo-EVs, but it remains unclear to what extent the process of surface blebbing is related mechanistically to the production of Apo-EVs. Here, we use the term “Apo-EV” to encompass all classes of subcellular vesicles produced as a consequence of apoptosis. These include small (~50–1,000 nm) as well as larger vesicles (1 to several microns in diameter), often

referred to as “apoptotic bodies,” which harbor caspase-modified autoantigens, nuclear remnants containing condensed chromatin, and well-defined organelles, such as mitochondria and endoplasmic reticulum. Among the smaller vesicles are likely to be exosomes of endosomal pathway origin and budding plasma membrane EVs also known as microvesicles or ectosomes (27). As with all EVs, the size of Apo-EVs matters—not only in relation to what molecular and organelle cargoes can be carried but also with respect to the specific contribution of molecular cargoes, such as cell surface proteins, to overall EV size (Figure 2). While Apo-EVs are undoubtedly heterogeneous both in size and content (28), the underlying causes of this heterogeneity remain obscure.

APO-EV PRODUCTION MECHANISMS

During apoptosis, caspase-dependent cleavage, and activation of Rho-activated kinase, ROCK I alters actomyosin contractility, resulting in membrane blebbing (30). Blebbing occurs independently of altered K⁺ and Cl⁻ channel activity that results in increased K⁺ permeability and the reduction of cell volume that accompanies apoptosis. Instead, bleb formation occurs as a consequence of detachment of the plasma membrane from the actin cortex and increased hydrostatic pressure generated by the actomyosin system (31). As a consequence, there is rapid local influx of cytosolic material and “ballooning” of the membrane, resulting in bleb enlargement. Although cytoskeletal proteins are lacking in newly formed blebs, as blebbing progresses, there is reassembly of the cortical cytoskeleton underneath the membrane. Treatment of cells with the ROCK inhibitor Y-27632 reduces both the formation of apoptotic bodies and the capacity for apoptotic-cell clearance (32). Formation of small Apo-EVs may also be regulated through similar ROCK-dependent mechanisms (33), as are EVs generated by a variety of tumor cell types (34).

It has been widely assumed that the plasma membrane of apoptotic cells, apoptotic blebs, and Apo-EVs are molecularly homogeneous, displaying broadly similar changes, such as phosphatidylserine (PtdSer) exposure. However, there is evidence that apoptotic bodies exhibit loss of membrane integrity that allows limited molecular exchange (35), which may allow selective release of molecules that are able to modulate innate inflammatory mechanisms. Protein release from apoptotic bodies, particularly of nucleosomal histones, was reduced following inhibition of activity of either ROCK or myosin ATPase (35). Loss of membrane permeability may be phased as apoptosis progresses, prior to the catastrophic loss of membrane integrity during secondary necrosis. Formation of Apo-EVs and gradual loss of membrane permeability could represent a mechanism to provide transient protection of proteins from local proteolytic degradation and/or clearance, potentially allowing signals relating to cellular demise to be disseminated distally, for example to other parts of the tumor microenvironment and to metastatic sites.

Studies of the recognition and phagocytosis of apoptotic cells have revealed potentially contrasting roles for membrane blebbing and the formation of apoptotic bodies. Formation of apoptotic blebs may promote phagocytosis of apoptotic cells. Compromised apoptotic cell uptake following inhibition of blebbing (36) could be partially reversed by addition of the PtdSer opsonin, MFG-E8. Other phospholipid binding proteins such as C1q have been demonstrated to bind avidly to apoptotic blebs and C1q binds to neuronal blebs, acting to augment phagocytosis by microglia (37). ROCK-dependent high-density opsonization of apoptotic blebs could generate a topology that promotes phagocyte recognition, providing an explanation for why low-level PtdSer exposure is not sufficient to signal phagocytosis of viable cells. Thus, membrane blebbing likely facilitates maintenance of self-tolerance and suppression of antitumor immunity




FIGURE 2 | Considerations of vesicular cargoes in relation to extracellular vesicle (EV) sizes. Schematic representations of Apo-EVs of ~500 nm (left) and 50 nm (right) are shown with delimiting lipid bilayer (green), a small mitochondrion (brown), ribosomes (gray), and examples of surface proteins all drawn approximately to scale. Note the significant potential impact of surface molecule size on total vesicle size in the case of small vesicles displaying relatively large surface molecules [measurement and representation of cell surface proteins adapted from Ref. (29)].

through direct effects on apoptotic cell clearance. Other phenomena related to vesiculation during apoptosis have also been noted recently. Following the description of apoptopodia—fine protuberances from apoptotic cells that appear to be involved in the release of larger varieties of Apo-EVs ($>1\ \mu\text{m}$) (38)—EV production from certain apoptotic cell types has been observed to involve fragmentation of membrane protrusions resembling beads on a string (39). While the significance of these observations has not been fully elucidated, they provide clues as to the molecular events underlying the production of Apo-EVs and their cargo loading preferences. Intriguingly, Apo-EVs produced from beaded apoptopodia were found to be depleted of nuclear components including histones and nuclear DNA (39) that are well-known constituents of apoptotic bodies (40).

CARGOES AND FUNCTIONAL ACTIVITIES

While EVs ostensibly of non-apoptotic cell origins have been the subject of intense research in cancer biology in recent years, the biology of Apo-EVs remains less clear. Following on from seminal work showing that glioblastoma EVs carry RNA and protein cargoes having tumor growth-promoting properties and utility as diagnostic biomarkers (41), a wealth of evidence now implicates EVs in regulating tumor growth and metastatic spread through control of angiogenesis, drug resistance, and antitumor immunity. Furthermore, the roles of EVs in intercellular communication in the tumor microenvironment are becoming better defined. Taking some recent examples, in murine melanoma, tumor cell-derived exosomes have been reported to promote the accumulation of pro-tumor macrophages *via* their ability to educate mesenchymal stromal cells which, like tumor-associated macrophages, are able to promote malignant disease *via* multiple modes, including growth factor production, suppression of antitumor immunity and angiogenesis (42). EVs from circulating tumor cells are also generated under conditions of shear flow. These EVs may play important roles in establishing the metastatic niche in the lung through interaction with the lung vasculature and rapidly accumulating myeloid cells (which phagocytose them) (43). It is noteworthy that EVs provide an intercellular signaling mechanism to transfer drug resistance to susceptible cells. For example, transfer of resistance to the multi-receptor tyrosine kinase inhibitor drug, Sunitinib can be achieved by a long, non-coding RNA (lncARSA) which acts by competing for binding to mir-34 and mir-449 to promote AXL and c-MET expression in renal cell carcinoma cells by carriage in exosomes and transfer to susceptible cells, thereby propagating resistance (44). Intriguingly, EVs isolated from cancer-associated fibroblasts are able to alter the metabolic profile of pancreatic tumor cells that interact with, and internalize them (45). Metabolic reprogramming by EVs involved inhibition of oxidative phosphorylation by mitochondria resulting in promotion of glycolysis and glutamine-dependent reductive carboxylation (46) in the recipient tumor cells. Furthermore, EVs were found to be capable of transferring multiple metabolic constituents including amino acids, lipids, citrate, and pyruvate among others, to tumor cells endowing them with the capacity to grow in nutrient-deficient media *in vitro* (45). These results strongly support the notion that

EVs in the tumor microenvironment provide tumor cells with critical metabolic signals and constituents which permit growth of tumor clones under conditions of stress such as hypoxia and nutrient deprivation.

The extent to which Apo-EVs—including the larger variety, apoptotic bodies—can perform similarly diverse functions to their non-apoptotic counterparts awaits detailed clarification. However, several studies would tend to suggest that Apo-EVs represent far more than biological “waste disposal” units. We support the definition of Apo-EVs as those EVs, regardless of size or cargo, that are produced as a consequence of activation of the apoptosis effector machinery (such as executioner caspase activation) and that ultimately results in cell death. Thus, active Apo-EV production presages cell death and a major challenge for the allocation of functional properties to Apo-EVs specifically will be their discrimination from EVs produced by cells activated by other (for example, stress) pathways, including those en route to apoptosis. Like all EVs, Apo-EVs are overtly heterogeneous as illustrated by their size profile alone, which, ranges from around 30 nm to several microns (47, 48). To what extent size of Apo-EVs relates to functional properties is largely unknown, although small EVs (30–100 nm, which the authors termed “exosome-like”) produced by vascular endothelial cells downstream of caspase-3 activation were found to be distinct from their larger counterparts (microvesicles and apoptotic bodies) both in cargo composition and biological function (48). Vascular endothelial cell-derived apoptotic bodies carry histones and other nuclear proteins as well as abundant markers of organelles including mitochondria, endoplasmic reticulum, and ribosomes (48), confirming observations of apoptotic body cargoes in other systems. By contrast, the exosome-like EVs were found to be enriched in lysosomal, basement membrane and extracellular matrix proteins (48). Intriguingly, certain hallmark proteins of exosomes, including TSG101, CD9, and CD81, were missing from the exosome-like EVs whereas others, notably fibronectin, syntenin and translationally controlled tumor protein (TCTP) were present. Critically, exosome-like EVs were found to be immunogenic, in contrast to apoptotic bodies (48), confirming the presumption that the latter, as major remnants of apoptotic cells, are generally tolerogenic.

These recent studies extend earlier investigations demonstrating the segregation of nuclear components into granular and vesicular structures and extrusion from the cell in EV-like structures and apoptotic bodies (49–54). Strikingly, DNA and RNA from apoptotic cells have been described as segregating into non-overlapping vesicular entities, adding to the complexity of Apo-EV heterogeneity. It is well established that the blebs of apoptotic cell surfaces harbor antigens of common significance in autoimmune disease, including the ribonucleoproteins La and Ro and nucleosomal DNA (55). The immunogenicity of exosome-like EVs from apoptotic endothelial cells adds a further dimension to this phenomenon. Thus, the C-terminal fragment (LG3) of the basement membrane component Perlecan carried by the exosome-like EVs is highly immunogenic and may be responsible for the production of autoantibodies that can severely compromise successful renal transplantation (48). Substantial further investigations are warranted in order to clarify the differential

capacity of apoptotic cells and their derived vesicles to modulate tolerance and immunity.

Besides immuno-regulatory properties, Apo-EVs have additional functional attributes based, like other EV classes, on their ability to transfer bioactive molecules to “target” cells. For example, apoptotic bodies (1–4 μm) derived from mature endothelial cells have been shown to stimulate the proliferation and differentiation of circulating endothelial progenitor cells (56). Indeed, Apo-EVs of endothelial cell origin carry a variety of biologically active components in addition to the aforementioned immunogenic Perlecan LG3, including TCTP, which can inhibit apoptosis in vascular smooth muscle cells (57). Apo-EVs may also allow the transfer of intact organelles between cells. In this context, it is noteworthy that mitochondrial transfer *via* EVs may represent an important response to stressful conditions as exemplified by the transfer of intact mitochondria from astrocytes to neurons in order to provide survival signals during the ischemic conditions of stroke (58). One of the most intriguing cargoes of Apo-EVs is genomic DNA since it has been shown that apoptotic bodies are able to mediate the horizontal transfer of DNA between somatic cells. While the details of the modes of transfer and fundamental roles of Apo-EVs (versus the remnants of apoptotic cells) have not been studied, DNA from apoptotic cells can undoubtedly be transferred to neighboring cells including tumor cells, endothelial cells, fibroblasts, and macrophages leading to apoptotic cell-derived gene expression in the recipient cells. In normal physiology, cells are protected by a DNA damage response requiring DNase II, Chk2, and p53/p21, and deficiency in p53 and p21 can ultimately render murine embryonic fibroblasts oncogenic following transfer of DNA from apoptotic cells harboring *c-myc* or *H-Ras* oncogenes in combination with a drug resistance gene (59–61). These results have significant implications not only for genomic stability and heterogeneity of tumor cells but also for the acquisition of aberrant DNA by non-tumor cell components of the ORN, notably endothelial cells, macrophages and fibroblasts, all of which have known capacity to engulf apoptotic cells and bodies. Such genetic changes in the ORN could provide important pro-oncogenic signals even if the resultant “exogenous” gene expression is transient.

CONCLUSION AND FUTURE PERSPECTIVES

While it is clear that the breakdown of apoptotic cells into membrane-bounded fragments of broad size ranges varies between different cell types, the full extent of the functional properties of Apo-EVs remains unknown. It has been reported that formation of “bite-sized” apoptotic bodies can aid in the phagocytic

clearance of dying cells (36). This may be important for the apoptotic-cell clearance processes of so-called non-professional (i.e., non-macrophage) phagocytes. However, macrophages and other phagocytes have overt capacity to engulf whole apoptotic cells rapidly (62). We propose that the most important function of Apo-EVs in the context of cancer is the propagation of intercellular signals of fundamental importance to the ORN. Understanding their modes of interaction with recipient cells, their mechanisms of internalization and intracellular processing will be crucial to understanding fully the physiological and pathological attributes of Apo-EVs. To date, virtually nothing is known of these processes, although it may be expected that some clearance/engulfment mechanisms of apoptotic cells and Apo-EVs will prove to share molecular components (**Figure 1**). It is noteworthy in this context that PtdSer exposed on EVs is involved in their uptake by target cells expressing PtdSer receptors such as TIM-4, known for phagocytosis of apoptotic cells (63). A critical question is whether endocytosed or phagocytosed Apo-EV cargo is necessarily degraded by lysosomes, as is generally assumed. Thus, the targeting mechanisms of Apo-EVs along with the destinies of their cargoes require detailed clarification.

Pro-inflammatory extracellular vesicles (EVs) are produced by macrophages responding to ATP *via* P2X7 receptors. It has been reported recently that this results in NLRP3 inflammasome activation in human macrophages, which consequently undergo vesicle-mediated unconventional secretion of IL-1 β (64). Conversely, alveolar macrophage-derived EVs have been shown to suppress airway inflammation (65). Thus, the vesicular intercommunication that results from tissue damage is likely to involve a varied mix of vesicle populations, including pro- and anti-inflammatory, derived not only from dying cells but also from their responsive neighbors or recruited phagocytes (**Figure 1**). Since the ORN represents a sector of the tumor microenvironment engaged in dysregulated, cell death-driven tissue repair and regeneration, it seems likely that the intercellular communications so achieved by EVs of the ORN will prove to overlap with those in healing or chronic wounds. Future work aimed at identifying the underlying mechanisms may yield novel molecular targets for both cancer and wound treatments.

AUTHOR CONTRIBUTIONS

Both authors planned and co-wrote the manuscript.

FUNDING

The authors' research is funded by Bloodwise and the Medical Research Council (UK).

REFERENCES

- Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. *Blood* (1992) 80:879–86.
- Westhoff MA, Marschall N, Debatin KM. Novel approaches to apoptosis-inducing therapies. *Adv Exp Med Biol* (2016) 930:173–204. doi:10.1007/978-3-319-39406-0_8
- Delbridge AR, Pang SH, Vandenberg CJ, Grabow S, Aubrey BJ, Tai L, et al. RAG-induced DNA lesions activate proapoptotic BIM to suppress lymphomagenesis in p53-deficient mice. *J Exp Med* (2016) 213(10):2039–48. doi:10.1084/jem.20150477
- Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* (2000) 100:57–70. doi:10.1016/S0092-8674(00)81683-9
- Bergmann A, Steller H. Apoptosis, stem cells, and tissue regeneration. *Sci Signal* (2010) 3:re8. doi:10.1126/scisignal.3145re8
- Vriz S, Reiter S, Galliot B. Cell death: a program to regenerate. *Curr Top Dev Biol* (2014) 108:121–51. doi:10.1016/B978-0-12-391498-9.00002-4

7. Fuchs Y, Steller H. Live to die another way: modes of programmed cell death and the signals emanating from dying cells. *Nat Rev Mol Cell Biol* (2015) 16:329–44. doi:10.1038/nrm3999
8. Perez-Garijo A, Steller H. Spreading the word: non-autonomous effects of apoptosis during development, regeneration and disease. *Development* (2015) 142:3253–62. doi:10.1242/dev.127878
9. Dabrowska C, Li M, Fan Y. Apoptotic caspases in promoting cancer: implications from their roles in development and tissue homeostasis. *Adv Exp Med Biol* (2016) 930:89–112. doi:10.1007/978-3-319-39406-0_4
10. Leoncini L, Del Vecchio MT, Megha T, Barbini P, Galieni P, Pileri S, et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. *Am J Pathol* (1993) 142:755–63.
11. Tormanen U, Eerola AK, Rainio P, Vahakangas K, Soini Y, Sormunen R, et al. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. *Cancer Res* (1995) 55:5595–602.
12. Stammler G, Sauerbrey A, Zintl F, Volm M. Apoptotic index, Fas and bcl-2 in initial and relapsed childhood acute lymphoblastic leukaemia. *Apoptosis* (1997) 2:377–83. doi:10.1023/A:1026405707823
13. Symmans WF, Cangiarella JF, Symmans PJ, Cohen JM, Yee HT, Bennett G, et al. Apoptotic index from fine needle aspiration cytology as a criterion to predict histologic grade of non-Hodgkin's lymphoma. *Acta Cytol* (2000) 44:194–204. doi:10.1159/000326360
14. Dworakowska D, Jassem E, Jassem J, Karmolinski A, Dworakowski R, Wirth T, et al. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression. *J Cancer Res Clin Oncol* (2005) 131:617–23. doi:10.1007/s00432-005-0010-7
15. Hilska M, Collan YU, VJ OL, Kossi J, Hirsimaki P, Laato M, et al. The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. *Dis Colon Rectum* (2005) 48:2197–208. doi:10.1007/s10350-005-0202-x
16. Sun B, Sun Y, Wang J, Zhao X, Wang X, Hao X. Extent, relationship and prognostic significance of apoptosis and cell proliferation in synovial sarcoma. *Eur J Cancer Prev* (2006) 15:258–65. doi:10.1097/01.cej.0000198896.02185.68
17. Boder J, Abdalla F, Elfaghieh M, Buhmeida A, Collan Y. Apoptotic activity in Libyan breast cancer. *World J Surg Oncol* (2012) 10:102. doi:10.1186/1477-7819-10-102
18. Hu Q, Peng J, Liu W, He X, Cui L, Chen X, et al. Elevated cleaved caspase-3 is associated with shortened overall survival in several cancer types. *Int J Clin Exp Pathol* (2014) 7:5057–70.
19. Bairey O, Zimra Y, Shaklai M, Okon E, Rabizadeh E. Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. *Clin Cancer Res* (1999) 5:2860–6.
20. Ichim G, Lopez J, Ahmed SU, Muthalagu N, Giampazolias E, Delgado ME, et al. Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. *Mol Cell* (2015) 57:860–72. doi:10.1016/j.molcel.2015.01.018
21. Li F, Huang Q, Chen J, Peng Y, Roop DR, Bedford JS, et al. Apoptotic cells activate the “phoenix rising” pathway to promote wound healing and tissue regeneration. *Sci Signal* (2010) 3:ra13. doi:10.1126/scisignal.2000634
22. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. *Nat Med* (2011) 17:860–6. doi:10.1038/nm.2385
23. Ford CA, Petrova S, Pound JD, Voss JJ, Melville L, Paterson M, et al. Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. *Curr Biol* (2015) 25:577–88. doi:10.1016/j.cub.2014.12.059
24. Lauber K, Herrmann M. Tumor biology: with a little help from my dying friends. *Curr Biol* (2015) 25:R198–201. doi:10.1016/j.cub.2015.01.040
25. Gregory CD, Ford CA, Voss JJ. Microenvironmental effects of cell death in malignant disease. *Adv Exp Med Biol* (2016) 930:51–88. doi:10.1007/978-3-319-39406-0_3
26. Gregory CD, Paterson M. An apoptosis-driven ‘onco-regenerative niche’: roles of tumour-associated macrophages and extracellular vesicles. *Philos Trans R Soc Lond B Biol Sci* (2018) 373:1–9. doi:10.1098/rstb.2017.0003
27. Lynch C, Panagopoulou M, Gregory CD. Extracellular vesicles arising from apoptotic cells in tumors: roles in cancer pathogenesis and potential clinical applications. *Front Immunol* (2017) 8:1174. doi:10.3389/fimmu.2017.01174
28. Turiak L, Misjak P, Szabo TG, Aradi B, Paloczi K, Ozohanics O, et al. Proteomic characterization of thymocyte-derived microvesicles and apoptotic bodies in BALB/c mice. *J Proteomics* (2011) 74:2025–33. doi:10.1016/j.jpro.2011.05.023
29. Barclay AN, Brown M, Law SKA, McKnight A, Tomlinson M, van der Merwe PA. *The Leucocyte Antigen Factsbook*. London: Academic Press (1997).
30. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. *Nat Cell Biol* (2001) 3:339–45. doi:10.1038/35070009
31. Charras GT, Yarrow JC, Horton MA, Mahadevan L, Mitchison TJ. Non-equilibration of hydrostatic pressure in blebbing cells. *Nature* (2005) 435:365–9. doi:10.1038/nature03550
32. Orlando KA, Stone NL, Pittman RN. Rho kinase regulates fragmentation and phagocytosis of apoptotic cells. *Exp Cell Res* (2006) 312:5–15. doi:10.1016/j.yexcr.2005.09.012
33. Sapet C, Simoncini S, Loriod B, Puthier D, Sampol J, Nguyen C, et al. Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. *Blood* (2006) 108:1868–76. doi:10.1182/blood-2006-04-014175
34. Li B, Antonyak MA, Zhang J, Cerione RA. RhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells. *Oncogene* (2012) 31:4740–9. doi:10.1038/onc.2011.636
35. Wickman GR, Julian L, Mardilovich K, Schumacher S, Munro J, Rath N, et al. Blebs produced by actin-myosin contraction during apoptosis release damage-associated molecular pattern proteins before secondary necrosis occurs. *Cell Death Differ* (2013) 20:1293–305. doi:10.1038/cdd.2013.69
36. Orlando KA, Pittman RN. Rho kinase regulates phagocytosis, surface expression of GlcNAc, and Golgi fragmentation of apoptotic PC12 cells. *Exp Cell Res* (2006) 312:3298–311. doi:10.1016/j.yexcr.2005.09.012
37. Fraser DA, Pisalyaput K, Tenner AJ. C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production. *J Neurochem* (2010) 112:733–43. doi:10.1111/j.1471-4159.2009.06494.x
38. Poon IK, Chiu YH, Armstrong AJ, Kinchen JM, Juncadella JJ, Bayliss DA, et al. Unexpected link between an antibiotic, pannexin channels and apoptosis. *Nature* (2014) 507:329–34. doi:10.1038/nature13147
39. Atkin-Smith GK, Tixeira R, Paone S, Mathivanan S, Collins C, Liem M, et al. A novel mechanism of generating extracellular vesicles during apoptosis via a beads-on-a-string membrane structure. *Nat Commun* (2015) 6:7439. doi:10.1038/ncomms8439
40. Wickman G, Julian L, Olson MF. How apoptotic cells aid in the removal of their own cold dead bodies. *Cell Death Differ* (2012) 19:735–42. doi:10.1038/cdd.2012.25
41. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat Cell Biol* (2008) 10:1470–6. doi:10.1038/ncb1800
42. Lin LY, Du LM, Cao K, Huang Y, Yu PF, Zhang LY, et al. Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities. *Oncogene* (2016) 35(46):6038–42. doi:10.1038/onc.2016.131
43. Headley MB, Bins A, Nip A, Roberts EW, Looney MR, Gerard A, et al. Visualization of immediate immune responses to pioneer metastatic cells in the lung. *Nature* (2016) 531:513–7. doi:10.1038/nature16985
44. Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. *Cancer Cell* (2016) 29:653–68. doi:10.1016/j.ccell.2016.03.004
45. Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, et al. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. *Elife* (2016) 5:e10250. doi:10.7554/eLife.10250
46. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. *Nature* (2011) 481:385–8. doi:10.1038/nature10642
47. Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. *J Neurooncol* (2013) 113:1–11. doi:10.1007/s11060-013-1084-8
48. Dieude M, Bell C, Turgeon J, Beillevaire D, Pomerleau L, Yang B, et al. The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. *Sci Transl Med* (2015) 7:318ra200. doi:10.1126/scitranslmed.aac9816

49. Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. *Nat Commun* (2011) 2:180. doi:10.1038/ncomms1180
50. Halicka HD, Bedner E, Darzynkiewicz Z. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. *Exp Cell Res* (2000) 260:248–56. doi:10.1006/excr.2000.5027
51. Biggiogera M, Bottone MG, Pellicciari C. Nuclear RNA is extruded from apoptotic cells. *J Histochem Cytochem* (1998) 46:999–1005. doi:10.1177/002215549804600903
52. Biggiogera M, Bottone MG, Martin TE, Uchiumi T, Pellicciari C. Still immunodetectable nuclear RNPs are extruded from the cytoplasm of spontaneously apoptotic thymocytes. *Exp Cell Res* (1997) 234:512–20. doi:10.1006/excr.1997.3657
53. Biggiogera M, Bottone MG, Pellicciari C. Nuclear ribonucleoprotein-containing structures undergo severe rearrangement during spontaneous thymocyte apoptosis. A morphological study by electron microscopy. *Histochem Cell Biol* (1997) 107:331–6. doi:10.1007/s004180050118
54. Scovassi AI, Bottone MG, Biggiogera M, Pellicciari C. Dynamic relocation of nuclear proteins during the execution phase of apoptosis. *Biochem Pharmacol* (2008) 76:1440–50. doi:10.1016/j.bcp.2008.06.005
55. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. *J Exp Med* (1994) 179:1317–30. doi:10.1084/jem.179.4.1317
56. Hristov M, Erl W, Linder S, Weber PC. Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro. *Blood* (2004) 104:2761–6. doi:10.1182/blood-2003-10-3614
57. Sirois I, Raymond MA, Brassard N, Cailhier JF, Fedjaev M, Hamelin K, et al. Caspase-3-dependent export of TCTP: a novel pathway for antiapoptotic intercellular communication. *Cell Death Differ* (2011) 18:549–62. doi:10.1038/cdd.2010.126
58. Hayakawa K, Esposito E, Wang X, Terasaki Y, Liu Y, Xing C, et al. Transfer of mitochondria from astrocytes to neurons after stroke. *Nature* (2016) 535:551–5. doi:10.1038/nature18928
59. Holmgren L, Szeles A, Rajnavolgyi E, Folkman J, Klein G, Ernberg I, et al. Horizontal transfer of DNA by the uptake of apoptotic bodies. *Blood* (1999) 93:3956–63.
60. Bergsmedh A, Szeles A, Henriksson M, Bratt A, Folkman MJ, Spetz AL, et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies. *Proc Natl Acad Sci U S A* (2001) 98:6407–11. doi:10.1073/pnas.101129998
61. Bergsmedh A, Ehnfors J, Kawane K, Motoyama N, Nagata S, Holmgren L. DNase II and the Chk2 DNA damage pathway form a genetic barrier blocking replication of horizontally transferred DNA. *Mol Cancer Res* (2006) 4:187–95. doi:10.1158/1541-7786.MCR-05-0262
62. Savill J. The innate immune system: recognition of apoptotic cells. In: Gregory CD, editor. *Apoptosis and the Immune Response*. New York: Wiley-Liss (1995). p. 341–69.
63. French KC, Antonyak MA, Cerione RA. Extracellular vesicle docking at the cellular port: extracellular vesicle binding and uptake. *Semin Cell Dev Biol* (2017) 67:48–55. doi:10.1016/j.semcdb.2017.01.002
64. Valimaki E, Cypryk W, Virkanen J, Nurmi K, Turunen PM, Eklund KK, et al. Calpain activity is essential for atp-driven unconventional vesicle-mediated protein secretion and inflammasome activation in human macrophages. *J Immunol* (2016) 197(8):3315–25. doi:10.4049/jimmunol.1501840
65. Han CZ, Juncadella IJ, Kinchen JM, Buckley MW, Klibanov AL, Dryden K, et al. Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation. *Nature* (2016) 539:570–4. doi:10.1038/nature20141

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Gregory and Dransfield. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.